PIER: ranibizumab for neovascular age-related macular degeneration


September 1, 2010

Clinical trial

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.

Abraham P, Yue H, Wilson L.

Am J Ophthalmol. 2010 Sep;150(3):315-324.e1.
Full text | Metrics.

Share This Article :

Updated on March 7th, 2022

Source Archive